Literature DB >> 12943895

Economic implications of nesiritide versus dobutamine in the treatment of patients with acutely decompensated congestive heart failure.

Gregory de Lissovoy1, David M Stier, Gabrielle Ciesla, Mark Munger, Andrew J Burger.   

Abstract

Pooled data from trials comparing nesiritide with dobutamine for treatment of acute decompensated congestive heart failure were combined with national hospital cost data in an economic model. Results indicate that the acquisition cost of nesiritide is fully offset by decreased hospital costs.

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12943895     DOI： 10.1016/s0002-9149(03)00742-2

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN： 0002-9149            Impact factor:   2.778


  4 in total

Review 1.  Nesiritide in acute decompensated heart failure: current status and future perspectives.

Authors:  Selma F Mohammed; Josef Korinek; Horng H Chen; John C Burnett; Margaret M Redfield
Journal:  Rev Cardiovasc Med       Date:  2008       Impact factor: 2.930

2.  A prospective evaluation of nesiritide in the treatment of pediatric heart failure.

Authors:  J L Jefferies; S W Denfield; J F Price; W J Dreyer; C J McMahon; M A Grenier; J J Kim; V V Dimas; S K Clunie; B S Moffett; A C Chang; T I Wann; E O Smith; J A Towbin
Journal:  Pediatr Cardiol       Date:  2006 Jul-Aug       Impact factor: 1.655

3.  Retraction. rhBNP therapy can improve clinical outcomes and reduce in-hospital mortality compared with dobutamine in heart failure patients: a meta-analysis.

Authors:  Ming-Yi Lv; Shu-Ling Deng; Xiao-Feng Long
Journal:  Br J Clin Pharmacol       Date:  2015-11-28       Impact factor: 4.335

Review 4.  Natriuretic peptides: their structures, receptors, physiologic functions and therapeutic applications.

Authors:  Lincoln R Potter; Andrea R Yoder; Darcy R Flora; Laura K Antos; Deborah M Dickey
Journal:  Handb Exp Pharmacol       Date:  2009
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.